Theriva Biologics, Inc. Financial Ratios
TOVX|FY2011 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2011 SEC 10-K data.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.80 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2011)
Return on Equity
-48.3%
Profit Margin
-65.5%
Net Income / Revenue
Asset Turnover
0.64
Revenue / Total Assets
Equity Multiplier
1.16
Total Assets / Equity
Composite: -48.3% (reported: -48.3%)
Profitability
Gross Margin
-
Operating Margin
-
EBITDA
-$1.4M
EBITDA Margin
-52.2%
Liquidity
Current Ratio
7.09
Quick Ratio
7.09
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.64
Inventory Turnover
-
Days Sales Outstanding
47 days
As of FY2011 · SEC 10-K · Updated Jun 24, 2026
Earnings Quality
Accrual Ratio
-13.8%
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.